These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23583610)

  • 1. RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.
    Keiser MS; Geoghegan JC; Boudreau RL; Lennox KA; Davidson BL
    Neurobiol Dis; 2013 Aug; 56():6-13. PubMed ID: 23583610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.
    Keiser MS; Boudreau RL; Davidson BL
    Mol Ther; 2014 Mar; 22(3):588-595. PubMed ID: 24419082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1.
    Keiser MS; Monteys AM; Corbau R; Gonzalez-Alegre P; Davidson BL
    Ann Neurol; 2016 Nov; 80(5):754-765. PubMed ID: 27686464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of calbindin-D28k expression exacerbates SCA1 phenotype in a disease mouse model.
    Vig PJ; Wei J; Shao Q; Lopez ME; Halperin R; Gerber J
    Cerebellum; 2012 Sep; 11(3):718-32. PubMed ID: 22076800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy.
    Vig PJ; Hearst S; Shao Q; Lopez ME; Murphy HA; Safaya E
    Cerebellum; 2011 Jun; 10(2):254-66. PubMed ID: 21384195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
    Xia H; Mao Q; Eliason SL; Harper SQ; Martins IH; Orr HT; Paulson HL; Yang L; Kotin RM; Davidson BL
    Nat Med; 2004 Aug; 10(8):816-20. PubMed ID: 15235598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinocerebellar ataxia type 1--modeling the pathogenesis of a polyglutamine neurodegenerative disorder in transgenic mice.
    Clark HB; Orr HT
    J Neuropathol Exp Neurol; 2000 Apr; 59(4):265-70. PubMed ID: 10759181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1.
    Ju H; Kokubu H; Todd TW; Kahle JJ; Kim S; Richman R; Chirala K; Orr HT; Zoghbi HY; Lim J
    J Neurosci; 2013 May; 33(22):9328-36. PubMed ID: 23719801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Purkinje cell miRNA expression and SCA1 pathogenesis.
    Rodriguez-Lebron E; Liu G; Keiser M; Behlke MA; Davidson BL
    Neurobiol Dis; 2013 Jun; 54():456-63. PubMed ID: 23376683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
    Cummings CJ; Orr HT; Zoghbi HY
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract.
    Yue S; Serra HG; Zoghbi HY; Orr HT
    Hum Mol Genet; 2001 Jan; 10(1):25-30. PubMed ID: 11136710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease.
    Gao Y; Zu T; Low WC; Orr HT; McIvor RS
    Cell Transplant; 2008; 17(7):723-34. PubMed ID: 19044200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
    Zu T; Duvick LA; Kaytor MD; Berlinger MS; Zoghbi HY; Clark HB; Orr HT
    J Neurosci; 2004 Oct; 24(40):8853-61. PubMed ID: 15470152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathogenesis of spinocerebellar ataxia type 1 disease.
    Kang S; Hong S
    Mol Cells; 2009 Jun; 27(6):621-7. PubMed ID: 19572115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acids in a region of ataxin-1 outside of the polyglutamine tract influence the course of disease in SCA1 transgenic mice.
    Skinner PJ; Vierra-Green CA; Emamian E; Zoghbi HY; Orr HT
    Neuromolecular Med; 2002; 1(1):33-42. PubMed ID: 12025814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis.
    Crespo-Barreto J; Fryer JD; Shaw CA; Orr HT; Zoghbi HY
    PLoS Genet; 2010 Jul; 6(7):e1001021. PubMed ID: 20628574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.
    Hearst SM; Shao Q; Lopez M; Raucher D; Vig PJ
    Cerebellum; 2014 Oct; 13(5):596-606. PubMed ID: 24930030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the ataxin-1 interaction network and its impact on spinocerebellar ataxia type 1.
    Chen JM; Chen SK; Jin PP; Sun SC
    Hum Genomics; 2022 Jul; 16(1):29. PubMed ID: 35906672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP7, a ubiquitin-specific protease, interacts with ataxin-1, the SCA1 gene product.
    Hong S; Kim SJ; Ka S; Choi I; Kang S
    Mol Cell Neurosci; 2002 Jun; 20(2):298-306. PubMed ID: 12093161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel function of Ataxin-1 in the modulation of PP2A activity is dysregulated in the spinocerebellar ataxia type 1.
    Sánchez I; Piñol P; Corral-Juan M; Pandolfo M; Matilla-Dueñas A
    Hum Mol Genet; 2013 Sep; 22(17):3425-37. PubMed ID: 23630944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.